(Sharecast News) - Data analytics firm Ixico has secured a contract for neuroimaging solutions with a "large global pharmaceutical company".
Ixico said on Tuesday that the Phase IIB trial would investigate the mystery group's orphan drug designated clinical asset for the treatment of Huntington's disease, a progressive and devastating neurodegenerative disorder
The AIM-listed group highlighted that the contract was already included in management expectations for the current financial year but did add to its "strong order book".
Chief commercial officer Lammert Albers said: "We are delighted to be chosen to take part in this HD study to advance development of promising medical treatments for this devastating rare disease.
"This contract and new partnership will further endorse our breakthrough neuroimaging technologies with large pharma sponsors across the full spectrum of the drug development pathway."
As of 0925 GMT, Ixico shares were up 2.92% at 110.64p.
Ixico (IXI)15 Apr 2024 14:25
Ixico inks supply agreement with Life Molecular Imaging for Neuraceq
(Alliance News) - Ixico PLC on Monday said it has signed a supply agreement with Life Molecular Imaging GmbH, in a deal the company says will compleme...